For many patients in East Africa, “Immunotherapy” has long felt like a luxury treatment available only to those who could travel abroad. At Shabaha Cancer Centre, we are committed to changing that narrative. Immunotherapy represents a revolutionary shift in oncology, focusing on empowering the patient’s own immune system to identify and destroy cancer cells with precision.
We are proud to be the pioneers of the Nivolumab Access Program in Kenya. Nivolumab is a sophisticated immunotherapy drug that helps the immune system recognize and attack cancer cells. While traditionally very expensive, our access program is specifically structured to significantly lower the financial barrier for patients. This initiative is part of our core mission: bridging the gap between global medical innovation and local affordability.
Why Choose Shabaha for Immunotherapy?
Our clinical team, led by Dr. Noordin Bashir Somo, monitors every infusion with expert care. We don’t just provide the medication; we provide a safe, world-class environment in our modern infusion suite, ensuring that your journey with immunotherapy is as effective and comfortable as possible.
Who Can Benefit?
Immunotherapy has shown remarkable success in treating various types of cancer, particularly:
Advanced Lung Cancer: Providing new hope for patients who have not responded to traditional chemotherapy.
Kidney Cancer (Renal Cell Carcinoma): Improving long-term survival rates.
Melanoma and Skin Cancers: Targeting aggressive cells with precision.
